Table 5.
Clinical trials of H101 in recent years
| Clinical Registration Number | Title | Investigator | Combined therapies | Indication | Time | Clinical stages |
|---|---|---|---|---|---|---|
| ChiCTR2100051250 | Observation of the Clinical Efficacy of Recombinant Human Adenovirus Type 5 Intraperitoneal Injection Compared with Cisplatin in the Treatment of Malignant Ascites | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Single drug | Malignant pleural/peritoneal effusion | 2021/10-2023/12 | Others |
| NCT05051696 | Intra-Tumor Injection of Oncolytic Viruses H101 Combined with or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies | First Affiliated Hospital of Xi’an Jiaotong University | Radiotherapy | Gynecological cancer | 2021/09-2023/12 | Others |
| ChiCTR2100045010 | Recombinant Human Adenovirus Type 5 Compared with Intraperitoneal Injection of Cisplatin in the Treatment of Malignant Ascites | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Single drug | Malignant pleural/peritoneal effusion | 2021/04-2023/12 | Others |
| NCT04771676 | Intraperitoneal Injection of Oncolytic Viruses H101 for Patients with Refractory Malignant Ascites | Fudan University Shanghai Cancer Center | Single drug | Malignant pleural/peritoneal effusion | 2021/03-2022/12 | II |
| ChiCTR2000036827 | Clinical Study on the Efficacy and Safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) Combined With PD-1 Monoclonal Antibody and Anti-Vascular Drugs in the Treatment of Advanced Malignant Melanoma with Liver Metastasis | Shanghai Skin Disease Hospital | Immunotheray | Melanoma | 2020/10-2022/09 | 0 |
| ChicTR2000037525 | The Efficacy and Safety of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined with Recombinant Human Adenovirus Type 5 and Chemotherapy in the Treatment of Metastatic Osteosarcoma: A Prospective, Single-Arm, Exploratory Trial | Shanghai Sixth People’s Hospital | Immunotheray + Chemotheray | Osteosarcoma | 2020/10-2022/09 | II |
| ChiCTR2000033959 | Clinical Study on the Efficacy and Safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) Combined With PD-1 Monoclonal Antibody in the Treatment of Advanced Malignant Melanoma | Shanghai Tenth People’s Hospital | Immunotheray | Melanoma | 2019/12-2022/04 | IV |
| ChiCTR1900027922 | Clinical Study for Efficacy and Safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) Combined with Mfolfox6+ Bevacizumab in the Treatment of Unresectable Colorectal Adenocarcinoma with Liver Metastases | Shanghai Tenth People’s Hospital | Chemotherapy + Radiotherapy | Liver metastases of colorectal cancer | 2019/10-2021/10 | IV |
| ChiCTR1900025112 | Therapeutic Effect of Oncorine Intratumor Injection Combined with Sintilimab and Tegafur, Gimeracil and Oteracil Porassium Capsules in Advanced Pancreatic Cancer | Affiliated Hospital of Nantong university | Chemotherapy | Pancreatic cancer | 2019/09-2021/08 | IV |
| NCT03780049 | HAIC Plus H101 Vs HAIC Alone for Unresectable HCC At BCLC A-B | Sun Yat-sen University | Chemotherapy | Liver cancer | 2018/10-2023/10 | III |
| ChiCTR1800017971 | Clinical Study of Recombinant Human Adenovirus Type 5 (H101) Combined with PD-1 Antibody in The Treatment of Advanced Solid Tumors | The Second Hospital of medical University | Immunotheray | Others | 2018/09-2022/09 | IV |
| NCT03790059 | Radiofrequency Ablation Combined with Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma | Institute of hepatobiliary surgery, Southwest Hospital | Radiotherapy | Liver cancer | 2016/10-2020/09 | Others |
| NCT02579564 | Systemic Chemotherapy Combined with Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | Xinqiao Hospital of Chongqing | Chemotherapy | Malignant pleural/peritoneal effusion/lung cancer | 2016/10-2018/12 | III |
| ChiCTR-OPN-15006746 | TAI Versus TAI Plus H101 on NSCLC | West China Hospital Sichuan University | Chemotherapy | Lung cancer | 2015/06-2017/06 | IV |
| ChiCTR-OPC-15006142 | The Treatment of Locally Advanced Cervical Cancer by Recombinant Human Adenovirus Type 5 Injection (H101) Combined with Radiotherapy and Chemotherapy | Cancer Hospital of The University of Chinese Academy of Sciences | Chemotherapy + Radiotherapy | Cervical cancer | 2015/03-2017/12 | II |
| NCT01869088 | TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | Cancer Center, Sun Yat-sen University | Chemotherapy | Liver cancer | 2013/01-2018/01 | III |
| ChiCTR2000037761 | Clinical Study on the Efficacy and Safety of Oncolytic Adenovirus Combined With PD-1 Monoclonal Antibody in Advanced Unresectable Malignant Melanoma | Shanghai Skin Disease Hospital | Immunotheray | Melanoma | ----- | 0 |